# Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

> **NCT05407155** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 56 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **COMBINATION_PRODUCT:** bevacizumab plus nab-paclitaxel and platinum

## Key facts

- **NCT ID:** NCT05407155
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-08-30
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407155, "Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05407155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*